Arbutus Biopharma Corp
- ABUS
- NASDAQ
- Biotechnology
- Hepatitis B Therapeutics
- RNAi Drug Development
$4.23
Today +0.24%Quote Oct 19, 2026, 08:00 PM UTC
−15.57%over the last month
Max drawdown −18.0%From 1-month high −15.6%3 months −6.4%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Arbutus Biopharma
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States.
Where the money comes from
Q2 2026 revenue $10.3M
- License$9.6M93.4%
- Service, Other$500,0004.9%
- Non-Cash Royalty$180,0001.8%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
19
Founded
2005
Market value
$838.0M
Quote Oct 19
Analyst target
$8.50
+100.9% from here
Floor
$4.19
0.9% below price
Resistance
$4.23
Price is above this level
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ABUSPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free